Kazia Therapeutics Limited

Healthcare · Biotechnology · Australia

Last price 8.5 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 116.48M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain met...